Again, short sited people. They don't want to sacrifice share of voice. Thats the model. There will be changes im sure but dont count on a major layoff anytime soon
If you think your going have a 4 product bag trying to service cornea specials and glaucoma specialists and OD's and general ophth. your crazy there will be overlaps for sure but they wont sacrifice the billion plus market potential. Could it be Xiidra and Pazeo sure, but it wont by Xiidra Simbrinza Pazeo Ciprodex and whatever else they have. still 700 million to go with Xiidra so its not an add to the bag.